---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-000156"
form_type: "8-K"
ticker: "RXST"
cik: "0001111485"
company_name: "RxSight, Inc."
filed_at: "2022-01-10T23:59:59+00:00"
generated_at: "2026-06-27T19:12:02.722386+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# RxSight Q4 revenue ~$8.4M (+71% YoY); full year 2021 revenue ~$22.6M (+54% YoY)

## Summary
- Q4 2021 revenue ~$8.4M, up 71% YoY; sold 45 LDDs (installed base 206) and 2,959 LALs.
- FY 2021 revenue ~$22.6M, up 54% YoY; 114 LDDs and 8,328 LALs sold.
- Cash, equivalents and short-term investments ~$159.3M as of Dec 31, 2021.
- CEO Ron Kurtz cites continued adoption and ActivShield rollout as growth drivers for 2022.
- Results are preliminary; audited Q4 and FY 2021 results expected in early March.

## SEC filing metadata
- accession: 0000950170-22-000156
- form_type: 8-K
- ticker: RXST
- cik: 0001111485
- company_name: RxSight, Inc.
- filed_at: 2022-01-10T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1111485/000095017022000156/0000950170-22-000156-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1111485/000095017022000156/rxst-20220109.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-000156
- JSON: https://secwatch.observer/filing/0000950170-22-000156.json
- Plain text: https://secwatch.observer/filing/0000950170-22-000156.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.